Walleye Capital’s Ascendis Pharma A/S ASND Stock Holding History

Walleye Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$595K	Sell	2,600 -200	-7%	-$44.8K	﹤0.01%	2518
2025 Q4	$597K	Buy	2,800 +2,500	+833%	+$516K	﹤0.01%	2844
2025 Q3	$59.6K	Buy	300 +200	+200%	+$37.3K	﹤0.01%	3940
2025 Q2	$17.3K	Sell	100 -500	-83%	-$81.4K	﹤0.01%	4255
2025 Q1	$93.5K	Buy	+600	New	+$85.7K	﹤0.01%	3654
2024 Q3	–	Sell	-1,700	Closed	-$232K	–	5259
2024 Q2	$232K	Sell	1,700 -100	-6%	-$13.6K	﹤0.01%	4190
2024 Q1	$272K	Sell	1,800 -700	-28%	-$99.9K	﹤0.01%	3743
2023 Q4	$315K	Sell	2,500 -600	-19%	-$59.8K	﹤0.01%	3339
2023 Q3	$290K	Buy	+3,100	New	+$290K	﹤0.01%	3264
2023 Q2	–	Sell	-4,400	Closed	-$472K	–	4293
2023 Q1	$472K	Sell	4,400 -1,100	-20%	-$126K	0.01%	1762
2022 Q4	$672K	Buy	5,500 +4,200	+323%	+$488K	0.01%	1250
2022 Q3	$134K	Buy	+1,300	New	+$123K	﹤0.01%	2298

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's ASND Position: Q1 2026 in Review

Walleye Capital reduced its Ascendis Pharma A/S (ASND) stake by 94% in Q1 2026, selling an estimated $132K and leaving 37 shares worth $8.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4169.

Walleye Capital first reported a position in ASND in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.97M in Q2 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Walleye Capital held 37 shares of Ascendis Pharma A/S worth $8.46K as of Q1 2026.
Walleye Capital sold 591 Ascendis Pharma A/S shares in Q1 2026, an estimated $132K.
Ascendis Pharma A/S made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4169 holding.
Walleye Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 8 quarters since.
Walleye Capital's Ascendis Pharma A/S position peaked at $6.97M in Q2 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.